See more : PAO TMK (TRMK.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Anglo American Platinum Limited (ANGPY) Income Statement Analysis – Financial Results
- Lancor Holdings Limited (LANCORHOL.BO) Income Statement Analysis – Financial Results
- Siemens Limited (SIEMENS.BO) Income Statement Analysis – Financial Results
- Kewaunee Scientific Corporation (KEQU) Income Statement Analysis – Financial Results
- PYX Resources Limited (PYX.L) Income Statement Analysis – Financial Results
Valeo Pharma Inc. (VPHIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.valeopharma.com
About Valeo Pharma Inc.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 53.91M | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M | 1.28M | 985.71K |
Cost of Revenue | 40.83M | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M | 747.09K | 2.35M |
Gross Profit | 13.08M | 6.28M | 3.96M | 1.38M | 1.40M | 832.97K | 530.40K | -1.37M |
Gross Profit Ratio | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% | 19.01% | 41.52% | -138.68% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 126.26K | 0.00 |
General & Administrative | 22.56M | 18.81M | 13.31M | 3.32M | 3.04M | 2.98M | 2.84M | 1.10M |
Selling & Marketing | 6.59M | 6.09M | 2.89M | 2.12M | 2.01M | 236.53K | 133.75K | 72.75K |
SG&A | 29.15M | 24.90M | 16.19M | 5.45M | 5.05M | 3.22M | 2.98M | 1.01M |
Other Expenses | 1.15M | 0.00 | 123.00K | 198.00K | 253.00K | 147.04K | 50.77K | 0.00 |
Operating Expenses | 30.31M | 25.39M | 16.65M | 5.68M | 5.14M | 3.26M | 3.14M | 1.01M |
Cost & Expenses | 71.14M | 46.86M | 26.25M | 11.77M | 10.31M | 6.81M | 3.89M | 3.36M |
Interest Income | 3.72M | 173.00K | 1.00K | 1.00K | 0.00 | 816.00 | 368.00 | 114.17K |
Interest Expense | 13.79M | 6.46M | 1.36M | 598.00K | 110.00K | 173.85K | 102.42K | 0.00 |
Depreciation & Amortization | 2.63M | 1.42M | 743.00K | 424.00K | 135.00K | 44.47K | 40.12K | 38.56K |
EBITDA | -11.39M | -17.56M | -11.86M | -3.74M | -3.41M | -2.33M | -2.55M | -2.34M |
EBITDA Ratio | -21.13% | -63.28% | -87.47% | -49.44% | -51.85% | -53.13% | -199.81% | -237.24% |
Operating Income | -17.23M | -19.60M | -12.94M | -4.12M | -3.55M | -2.37M | -2.59M | -2.38M |
Operating Income Ratio | -31.96% | -70.66% | -95.45% | -55.11% | -53.90% | -54.15% | -202.95% | -241.15% |
Total Other Income/Expenses | -10.58M | -7.32M | -1.42M | -644.00K | 122.00K | 28.00K | -1.86M | 460.53K |
Income Before Tax | -27.81M | -26.92M | -14.23M | -4.76M | -3.62M | -2.40M | -4.50M | -1.92M |
Income Before Tax Ratio | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% | -54.78% | -352.25% | -194.43% |
Income Tax Expense | 0.00 | -1.17M | 1.48M | 796.00K | 326.00K | 36.72K | -881.21K | -640.00K |
Net Income | -27.81M | -25.75M | -14.23M | -4.76M | -3.62M | -2.44M | -3.62M | -1.28M |
Net Income Ratio | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | -55.62% | -283.27% | -129.50% |
EPS | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
EPS Diluted | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
Weighted Avg Shares Out | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Weighted Avg Shares Out (Dil) | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Valeo Pharma reports record 4Q and full-year 2022 financial results
Valeo Pharma says Health Canada has accepted for review Veru's New Drug Submission for sabizabulin
7 Penny Stocks to Buy as a New Bull Market Emerges
Valeo Pharma says Frederic Fasano has stepped down as the company's president and chief operating officer
Valeo Pharma raises Q4 and FY2022 revenue guidance to record levels
Valeo Pharma enters into Canadian commercial services agreement with Veru for sabizabulin in COVID-19 treatment
Valeo Pharma announces record revenue of $6.1M for 3Q; forecasts more than $11M in revenue for 4Q
Valeo Pharma announces appointment of Kyle Steiger to role of senior vice-president and CCO
Valeo Pharma secures loan from Sagard Healthcare Partners to fund acquisitions of pharmaceutical therapies
Valeo Pharma enters into agreement with Kaleo to produce epinephrine auto-injector for Canadian market
Source: https://incomestatements.info
Category: Stock Reports